Eli Lilly Pays $100M for Rights to CSL’s Clazakizumab

Why It Matters

The acquisition gives Lilly a potential high‑margin biologic to diversify revenue beyond its diabetes and obesity hits, while intensifying competition in the fast‑growing IL‑6 cardiovascular market.

Key Takeaways

• Lilly pays $100M for CSL’s clazakizumab rights.
• IL‑6 inhibition targeted for cardiovascular disease expansion.
• CSL retains kidney disease indication, Lilly gains other uses.
• Industry rivals Novo Nordisk, Novartis also pursuing IL‑6 antibodies.
• Long‑acting injectables may improve adherence over daily pills.

Pulse Analysis

Eli Lilly has deepened its cardiometabolic portfolio by paying $100 million for the rights to clazakizumab, a monoclonal antibody that blocks interleukin‑6 (IL‑6). While CSL Behring will continue to develop the drug for preventing cardiovascular events in end‑stage kidney disease, Lilly will explore additional indications, likely focusing on the inflammatory component of atherosclerotic disease and heart failure. The move follows a broader industry shift toward targeting IL‑6, a cytokine implicated in chronic inflammation, as a way to complement the company’s existing diabetes and obesity blockbuster products. 4 billion respectively to secure pipelines aimed at cardiovascular outcomes.

Their candidates, ziltivekimab and pacibekitug, are in late‑stage trials that could soon deliver oral‑equivalent efficacy with less frequent dosing. Long‑acting injectables like clazakizumab promise improved patient adherence compared with daily pills, a known challenge in chronic disease management. As regulators increasingly favor therapies that demonstrate both clinical benefit and real‑world compliance, the market potential for IL‑6‑targeted biologics is expanding rapidly.

Lilly’s aggressive deal‑making—spanning gene‑editing partner Verve and inflammasome inhibitor Ventyx—signals a strategic push to own multiple inflammation pathways. If clazakizumab advances to market, it could become a high‑margin biologic that diversifies revenue beyond Mounjaro and Zepbound, which already generate more than half of the company’s $65 billion 2025 sales. However, the drug still faces Phase 3 risk and potential competition from rival antibodies. Successful commercialization would reinforce Lilly’s position as a leading cardiometabolic innovator and could accelerate the broader shift toward biologic therapies in cardiovascular care.

Deal Summary

Eli Lilly announced it will pay $100 million to CSL Limited for the rights to the IL‑6‑blocking antibody clazakizumab, with CSL retaining rights for cardiovascular prevention in end‑stage kidney disease patients. The deal includes an upfront payment and potential milestone and royalty payments.